Published in Lab Business Week, May 21st, 2006
The changes include a reduction in the number of total patients to be enrolled from 300 down to 243, as well as an increase in the randomization ratio of patients treated with CORTOSS to patients in the control group treated with an approved PMMA bone cement. The protocol now provides for the enrollment of 162 patients in the CORTOSS arm of the study and 81 patients in the control group, for an overall randomization of 2:1.
The prospective randomized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.